{"id":"https://openalex.org/W7128480469","doi":"https://doi.org/10.1080/13543784.2026.2628208","title":"Pharmacokinetics and safety of candidate biosimilar CT-P55 versus reference secukinumab: a three-arm, randomized, double-blinded, single-dose, multicenter, Phase I study","display_name":"Pharmacokinetics and safety of candidate biosimilar CT-P55 versus reference secukinumab: a three-arm, randomized, double-blinded, single-dose, multicenter, Phase I study","publication_year":2026,"publication_date":"2026-02-01","ids":{"openalex":"https://openalex.org/W7128480469","doi":"https://doi.org/10.1080/13543784.2026.2628208","pmid":"https://pubmed.ncbi.nlm.nih.gov/41665131"},"language":"en","primary_location":{"id":"doi:10.1080/13543784.2026.2628208","doi":"https://doi.org/10.1080/13543784.2026.2628208","is_oa":true,"landing_page_url":"https://doi.org/10.1080/13543784.2026.2628208","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/13543784.2026.2628208","source":{"id":"https://openalex.org/S131064935","display_name":"Expert Opinion on Investigational Drugs","issn_l":"1354-3784","issn":["1354-3784","1744-7658"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Investigational Drugs","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://www.tandfonline.com/doi/pdf/10.1080/13543784.2026.2628208","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5110349851","display_name":"Tomoko Hasunuma","orcid":"https://orcid.org/0000-0001-6241-7985","observed_orcids":["https://orcid.org/0000-0001-6241-7985"]},"institutions":[{"id":"https://openalex.org/I4210154200","display_name":"Kitasato Institute Hospital","ror":"https://ror.org/05js82y61","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210154200"]},{"id":"https://openalex.org/I64189623","display_name":"Kitasato University","ror":"https://ror.org/00f2txz25","country_code":"JP","type":"education","lineage":["https://openalex.org/I64189623"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Tomoko Hasunuma","raw_affiliation_strings":["Kitasato University Kitasato Institute Hospital"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kitasato University Kitasato Institute Hospital","institution_ids":["https://openalex.org/I4210154200","https://openalex.org/I64189623"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042617470","display_name":"Michio Yagi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210147193","display_name":"Yokkaichi Municipal Hospital","ror":"https://ror.org/03k36hk88","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210147193"]},{"id":"https://openalex.org/I4210166362","display_name":"Municipal Hirakata City Hospital","ror":"https://ror.org/05wvk1430","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210166362"]},{"id":"https://openalex.org/I4405255757","display_name":"Medical Corporation Kyowakai Senri Chuo Hospital","ror":"https://ror.org/03cymxs77","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4405255757"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Michio Yagi","raw_affiliation_strings":["Medical Corporation Heishinkai OPHAC Hospital"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Corporation Heishinkai OPHAC Hospital","institution_ids":["https://openalex.org/I4210147193","https://openalex.org/I4210166362","https://openalex.org/I4405255757"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5125543786","display_name":"Noboru Nakamichi","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Noboru Nakamichi","raw_affiliation_strings":["Yokohama Minoru Clinic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yokohama Minoru Clinic","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5125584900","display_name":"Andrew Blauvelt","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andrew Blauvelt","raw_affiliation_strings":["Blauvelt Consulting, LLC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Blauvelt Consulting, LLC","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085831636","display_name":"Diamant Tha\u00e7i","orcid":"https://orcid.org/0000-0001-8513-550X","observed_orcids":["https://orcid.org/0000-0001-8513-550X"]},"institutions":[{"id":"https://openalex.org/I9341345","display_name":"University of L\u00fcbeck","ror":"https://ror.org/00t3r8h32","country_code":"DE","type":"education","lineage":["https://openalex.org/I9341345"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Diamant Tha\u00e7i","raw_affiliation_strings":["University of L\u00fcbeck"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of L\u00fcbeck","institution_ids":["https://openalex.org/I9341345"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110545230","display_name":"JeeHye Suh","orcid":"https://orcid.org/0009-0005-9273-0784","observed_orcids":["https://orcid.org/0009-0005-9273-0784"]},"institutions":[{"id":"https://openalex.org/I4210158021","display_name":"Celltrion (South Korea)","ror":"https://ror.org/05k84m754","country_code":"KR","type":"company","lineage":["https://openalex.org/I4210158021"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"JeeHye Suh","raw_affiliation_strings":["Celltrion, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celltrion, Inc","institution_ids":["https://openalex.org/I4210158021"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055582974","display_name":"JungBin Cha","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158021","display_name":"Celltrion (South Korea)","ror":"https://ror.org/05k84m754","country_code":"KR","type":"company","lineage":["https://openalex.org/I4210158021"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"JungBin Cha","raw_affiliation_strings":["Celltrion, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celltrion, Inc","institution_ids":["https://openalex.org/I4210158021"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5125543775","display_name":"IIn Noh","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158021","display_name":"Celltrion (South Korea)","ror":"https://ror.org/05k84m754","country_code":"KR","type":"company","lineage":["https://openalex.org/I4210158021"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"IIn Noh","raw_affiliation_strings":["Celltrion, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celltrion, Inc","institution_ids":["https://openalex.org/I4210158021"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061028420","display_name":"Eunkyung Euni Lee","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158021","display_name":"Celltrion (South Korea)","ror":"https://ror.org/05k84m754","country_code":"KR","type":"company","lineage":["https://openalex.org/I4210158021"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"EunKyung Lee","raw_affiliation_strings":["Celltrion, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celltrion, Inc","institution_ids":["https://openalex.org/I4210158021"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5008286260","display_name":"Kim Alexander Papp","orcid":"https://orcid.org/0000-0001-9557-3642","observed_orcids":["https://orcid.org/0000-0001-9557-3642"]},"institutions":[{"id":"https://openalex.org/I185261750","display_name":"University of Toronto","ror":"https://ror.org/03dbr7087","country_code":"CA","type":"education","lineage":["https://openalex.org/I185261750"]},{"id":"https://openalex.org/I4210122653","display_name":"Probity Medical Research","ror":"https://ror.org/0222df516","country_code":"CA","type":"facility","lineage":["https://openalex.org/I4210122653"]}],"countries":["CA"],"is_corresponding":true,"raw_author_name":"Kim A. Papp","raw_affiliation_strings":["Alliance Clinical Trials and Probity Medical Research Inc","University of Toronto"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alliance Clinical Trials and Probity Medical Research Inc","institution_ids":["https://openalex.org/I4210122653"]},{"raw_affiliation_string":"University of Toronto","institution_ids":["https://openalex.org/I185261750"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":9,"corresponding_author_ids":["https://openalex.org/A5008286260"],"corresponding_institution_ids":["https://openalex.org/I185261750","https://openalex.org/I4210122653"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"35","issue":"2","first_page":"179","last_page":"188"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/secukinumab","display_name":"secukinumab","score":0.9980000257492065},{"id":"https://openalex.org/keywords/biosimilars","display_name":"biosimilars","score":0.9509999752044678},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.925000011920929},{"id":"https://openalex.org/keywords/immunogenicity","display_name":"immunogenicity","score":0.8840000033378601},{"id":"https://openalex.org/keywords/safety","display_name":"safety","score":0.5180000066757202},{"id":"https://openalex.org/keywords/neutralizing-antibodies","display_name":"neutralizing antibodies","score":0.6930000185966492},{"id":"https://openalex.org/keywords/tnf-receptor-antagonist","display_name":"TNF receptor antagonist","score":0.5220000147819519},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.7519999742507935},{"id":"https://openalex.org/keywords/single-dose-administration","display_name":"single-dose administration","score":0.5320000052452087},{"id":"https://openalex.org/keywords/bioequivalence","display_name":"bioequivalence","score":0.6880000233650208}],"concepts":[{"id":"https://openalex.org/C59491497","wikidata":"https://www.wikidata.org/wiki/Q864715","display_name":"Biosimilar","level":2,"score":0.8485000133514404},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7626000046730042},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6175000071525574},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6044999957084656},{"id":"https://openalex.org/C3018359032","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Safety profile","level":3,"score":0.3686999976634979},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.3644999861717224},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.35659998655319214},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.34610000252723694},{"id":"https://openalex.org/C44280652","wikidata":"https://www.wikidata.org/wiki/Q104837","display_name":"Phase (matter)","level":2,"score":0.34040001034736633},{"id":"https://openalex.org/C42404028","wikidata":"https://www.wikidata.org/wiki/Q864940","display_name":"Bioequivalence","level":3,"score":0.314300000667572},{"id":"https://openalex.org/C2777334693","wikidata":"https://www.wikidata.org/wiki/Q659446","display_name":"Maximum tolerated dose","level":3,"score":0.2879999876022339},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.28529998660087585},{"id":"https://openalex.org/C3019038264","wikidata":"https://www.wikidata.org/wiki/Q1418791","display_name":"Drug candidate","level":3,"score":0.2806999981403351},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.2732999920845032},{"id":"https://openalex.org/C63433958","wikidata":"https://www.wikidata.org/wiki/Q1774688","display_name":"Clinical pharmacology","level":2,"score":0.25859999656677246},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.25220000743865967}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007279","descriptor_name":"Injections, Subcutaneous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007564","descriptor_name":"Japan","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013810","descriptor_name":"Therapeutic Equivalency","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D059451","descriptor_name":"Biosimilar Pharmaceuticals","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D059451","descriptor_name":"Biosimilar Pharmaceuticals","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D059451","descriptor_name":"Biosimilar Pharmaceuticals","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1080/13543784.2026.2628208","doi":"https://doi.org/10.1080/13543784.2026.2628208","is_oa":true,"landing_page_url":"https://doi.org/10.1080/13543784.2026.2628208","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/13543784.2026.2628208","source":{"id":"https://openalex.org/S131064935","display_name":"Expert Opinion on Investigational Drugs","issn_l":"1354-3784","issn":["1354-3784","1744-7658"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Investigational Drugs","raw_type":"journal-article"},{"id":"pmid:41665131","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/41665131","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert opinion on investigational drugs","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1080/13543784.2026.2628208","doi":"https://doi.org/10.1080/13543784.2026.2628208","is_oa":true,"landing_page_url":"https://doi.org/10.1080/13543784.2026.2628208","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/13543784.2026.2628208","source":{"id":"https://openalex.org/S131064935","display_name":"Expert Opinion on Investigational Drugs","issn_l":"1354-3784","issn":["1354-3784","1744-7658"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Investigational Drugs","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320318316","display_name":"Celltrion","ror":"https://ror.org/05k84m754"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7128480469.pdf","grobid_xml":"https://content.openalex.org/works/W7128480469.grobid-xml"},"referenced_works_count":22,"referenced_works":["https://openalex.org/W1984846010","https://openalex.org/W2052951012","https://openalex.org/W2080237150","https://openalex.org/W2512873140","https://openalex.org/W2594240753","https://openalex.org/W2789710874","https://openalex.org/W2803993169","https://openalex.org/W2887422108","https://openalex.org/W2930875443","https://openalex.org/W2940671601","https://openalex.org/W2947452967","https://openalex.org/W2949137526","https://openalex.org/W2982689367","https://openalex.org/W3176834192","https://openalex.org/W3202295648","https://openalex.org/W4200323575","https://openalex.org/W4205317825","https://openalex.org/W4211182049","https://openalex.org/W4286262663","https://openalex.org/W4313487632","https://openalex.org/W4380881927","https://openalex.org/W4402013347"],"related_works":["https://openalex.org/W4402013347","https://openalex.org/W4403498878","https://openalex.org/W4378347895","https://openalex.org/W2480028188","https://openalex.org/W4385073877","https://openalex.org/W4399883248","https://openalex.org/W4379648580","https://openalex.org/W2921716909","https://openalex.org/W3107011196","https://openalex.org/W3124773781"],"abstract_inverted_index":{"Background":[0],"This":[1],"first-in-human":[2],"study":[3,36,203],"compared":[4],"the":[5,69,112,124],"pharmacokinetics,":[6],"safety,":[7],"and":[8,19,28,80,101,120,182,187],"immunogenicity":[9,183],"of":[10,58,118,159],"candidate":[11],"biosimilar":[12],"CT-P55":[13,160,173],"to":[14,52,77,163,184],"both":[15,164,185],"European":[16],"Union":[17],"(EU)-approved":[18],"United":[20],"States":[21],"(US)-licensed":[22],"secukinumab":[23,97,103,153,166,189],"in":[24,41,190],"healthy":[25,191],"participants.Research":[26],"design":[27],"methods":[29],"Three-arm,":[30],"double-blinded,":[31],"parallel-group,":[32],"single-dose,":[33],"Phase":[34],"1":[35],"conducted":[37],"across":[38,90],"four":[39],"centers":[40],"Japan":[42],"over":[43],"22":[44],"weeks.":[45],"Healthy":[46],"adult":[47],"males":[48],"were":[49,66,88,122,130,136,143],"randomized":[50],"(1:1:1)":[51],"a":[53],"single":[54],"150-mg":[55],"subcutaneous":[56],"dose":[57],"CTP55,":[59],"EU-approved,":[60],"or":[61],"US-licensed":[62,102,188],"secukinumab.":[63],"Primary":[64],"endpoints":[65],"area":[67],"under":[68],"concentration":[70,84],"\u2013":[71],"time":[72,75],"curve":[73],"from":[74],"zero":[76],"infinity":[78],"(AUC0\u2013inf)":[79],"maximum":[81],"serum":[82],"drug":[83],"(Cmax).Results":[85],"Baseline":[86],"characteristics":[87],"comparable":[89,162,180],"groups":[91],"(CT-P55":[92],"[n":[93,98,104],"=":[94,99,105],"57],":[95],"EU-approved":[96,186],"59],":[100],"56]).":[106],"The":[107,155,202],"90%":[108],"confidence":[109],"intervals":[110],"for":[111,138],"geometric":[113],"least":[114],"squares":[115],"mean":[116],"ratios":[117],"AUC0\u2013inf":[119],"Cmax":[121],"within":[123],"equivalence":[125],"margin":[126],"(80\u2013125%).":[127],"Safety":[128],"profiles":[129],"comparable.":[131],"218":[132],"treatment-emergent":[133],"adverse":[134,148],"events":[135],"reported":[137,151],"110":[139],"(65.5%)":[140],"participants;":[141],"most":[142],"Grade":[144],"1/2.":[145],"One":[146],"serious":[147],"event":[149],"was":[150,161],"(US-licensed":[152],"group).":[154],"low":[156],"immunogenic":[157],"profile":[158],"reference":[165],"groups,":[167],"with":[168],"no":[169],"neutralizing":[170],"antibodies":[171],"detected.Conclusions":[172],"exhibited":[174],"equivalent":[175],"pharmacokinetics":[176],"as":[177,179],"well":[178],"safety":[181],"Japanese":[192],"males.":[193],"Generalizability":[194],"may":[195],"be":[196],"limited":[197],"beyond":[198],"Asian":[199],"males.Trial":[200],"registration":[201],"is":[204],"registered":[205],"at":[206],"Clinicaltrials.gov":[207],"(NCT07054970).":[208]},"counts_by_year":[],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2026-02-11T00:00:00"}